AZN's Forxiga Gets EU Approval - Analyst Blog

By
A A A

Recently, AstraZeneca ( AZN ) and Bristol-Myers Squibb ( BMY ) announced that their type II diabetes candidate, Forxiga (dapagliflozin) has received European approval. The European Commission (EC) approved the once-daily oral product for improving glycemic control in type II diabetes patients above 18 years along with lifestyle management and other glucose-lowering products, such as insulin. Forxiga can be used as a monotherapy in patients who are intolerant to metformin.

The EU approval did not come as a surprise as earlier in April 2012 the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had issued a positive opinion regarding the approval of Forxiga in the EU.

We note that the regulatory path for Forxiga has been quite diverse as far as approval in the US and EU is concerned. The candidate received a complete response letter (CRL) in the US in January 2012.

The diabetes market, while crowded, represents significant commercial potential. Key players in the diabetes market include Merck ( MRK ), Eli Lilly ( LLY ) and Novo Nordisk ( NVO ) among others.

Neutral on AstraZeneca

We are encouraged by AstraZeneca's focus on the high-potential emerging markets. We are pleased with its efforts to expand its pipeline and portfolio through mergers and acquisitions.

The Ardelyx agreement, Ardea acquisition, the Amgen ( AMGN ) collaboration and the expansion of the diabetes alliance with Bristol-Myers, all these represent the company's efforts in this direction. We expect more such deals in the near term.

However, we remain concerned about the generic competition faced by the company's key products. In 2011, the company lost revenues worth almost $2 billion to generic competition. The weak late-stage pipeline at AstraZeneca coupled with the slow Brilinta uptake also bothers us.

We currently have a Neutral recommendation on AstraZeneca. The stock carries a Zacks #3 Rank (Hold rating) in the short run.



AMGEN INC (AMGN): Free Stock Analysis Report

ASTRAZENECA PLC (AZN): Free Stock Analysis Report

BRISTOL-MYERS (BMY): Free Stock Analysis Report

LILLY ELI & CO (LLY): Free Stock Analysis Report

MERCK & CO INC (MRK): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: AMGN , AZN , CHMP , CRL , EC

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

89%
50%
100%
100%

Most Active by Volume

49,523,442
  • $100.45 ▼ 1.16%
48,048,328
  • $16.735 ▼ 0.03%
46,715,831
  • $42.77 ▲ 0.52%
43,165,730
  • $17.61 ▲ 6.47%
42,133,643
  • $13.755 ▲ 29.89%
28,770,465
  • $75.93 ▲ 1.81%
25,931,647
  • $99.42 ▲ 0.91%
25,893,441
  • $3.58 ▼ 0.14%
As of 9/16/2014, 02:31 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com